East Tamaki-based medical equipment manufacturer Fisher & Paykel Healthcare (FPH) has provided an update on the first four months of the 2022 financial year, which ended July 31, 2021.
The company held a virtual-only annual shareholders’ meeting recently. FPH is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea (OSA). The company’s products are sold in more than 120 countries worldwide. It is listed on both the NZX and ASX.
Revenue for the first four months was $583 million, with 74 per cent of revenue from the company’s Hospital product group and 26 per cent from its Homecare product group.
In constant currency, revenue for the four months was 2 per cent below the prior comparable period, which was a period of high demand during the initial surges of Covid-19 in North America and Europe.
Managing director and CEO Lewis Gradon said, “We would like to express our gratitude for the incredible efforts of healthcare professionals who are caring for patients during another difficult year.
“We would also like to acknowledge the people of Fisher & Paykel Healthcare working behind the scenes in our manufacturing facilities, warehouses, offices and at home to meet the ongoing global demand for respiratory products during the pandemic,” said Gradon.
FPH shares on the NZX were on Thursday morning September 2 $32.79 a share (market cap $19.08 billion and 52-week high of $37.89) and on the ASX A$31.57 per share (market cap A$18.20b and 52-week high $A34.77).
